199005-58-8

Upstream product

• 1099-45-2 ethyl (triphenylphosphoranylidene)acetate 
• 199005-57-7 Boc-Gln(Trt)-H 
• 199005-56-6 [(S)-1-(Methoxy-methyl-carbamoyl)-3-(trityl-carbamoyl)-propyl]-carbamic acid tert-butyl ester 
• 132388-69-3 Boc-L-Gln(Trt)-OH 

Downstream Products

• 343566-87-0 trans-(4S)-4-Amino-6-(tritylcarbamoyl)hex-2-enoic Acid Ethyl Ester 
• 199005-74-8 (E)-(S)-4-tert-Butoxycarbonylamino-6-(trityl-carbamoyl)-hex-2-enoic acid 
• 1026736-84-4 (S)-4-tert-Butoxycarbonylamino-6-(trityl-carbamoyl)-hexanoic acid ethyl ester 
• 199006-04-7 (E)-(S)-4-((S)-2-tert-Butoxycarbonylamino-3-phenyl-propionylamino)-6-(trityl-carbamoyl)-hex-2-enoic acid ethyl ester 
• 1028287-69-5 [(S)-3-Methyl-1-((S)-1-{(E)-(S)-4-[1,2]oxazinan-2-yl-4-oxo-1-[2-(trityl-carbamoyl)-ethyl]-but-2-enylcarbamoyl}-2-phenyl-ethylcarbamoyl)-butyl]-carbamic acid benzyl ester 
• 1026278-99-8 [(S)-3-Methyl-1-((S)-1-{(E)-(S)-3-(methyl-phenyl-carbamoyl)-1-[2-(trityl-carbamoyl)-ethyl]-allylcarbamoyl}-2-phenyl-ethylcarbamoyl)-butyl]-carbamic acid benzyl ester 
• 1026846-79-6 [(S)-1-((S)-1-{(E)-(S)-4-(2,3-Dihydro-indol-1-yl)-4-oxo-1-[2-(trityl-carbamoyl)-ethyl]-but-2-enylcarbamoyl}-2-phenyl-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid benzyl ester 
• 1026074-37-2 (E)-(S)-4-[(S)-2-((S)-2-Benzyloxycarbonylamino-4-methyl-pentanoylamino)-3-phenyl-propionylamino]-6-(trityl-carbamoyl)-hex-2-enoic acid benzyl ester 
• 1026700-09-3 [(S)-3-Methyl-1-((S)-1-{(E)-(S)-4-oxo-4-(2-oxo-oxazolidin-3-yl)-1-[2-(trityl-carbamoyl)-ethyl]-but-2-enylcarbamoyl}-2-phenyl-ethylcarbamoyl)-butyl]-carbamic acid benzyl ester 
• 1027568-23-5 [(S)-3-Methyl-1-((S)-1-{(E)-(S)-4-(3-methyl-2-oxo-imidazolidin-1-yl)-4-oxo-1-[2-(trityl-carbamoyl)-ethyl]-but-2-enylcarbamoyl}-2-phenyl-ethylcarbamoyl)-butyl]-carbamic acid benzyl ester 
• 1027736-55-5 [(S)-1-((S)-1-{(E)-(S)-4-(3,4-Dihydro-2H-quinolin-1-yl)-4-oxo-1-[2-(trityl-carbamoyl)-ethyl]-but-2-enylcarbamoyl}-2-phenyl-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid benzyl ester 
• 1026747-53-4 [(S)-1-((S)-1-{(E)-(S)-4-(5-Bromo-2,3-dihydro-indol-1-yl)-4-oxo-1-[2-(trityl-carbamoyl)-ethyl]-but-2-enylcarbamoyl}-2-phenyl-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid benzyl ester 
• 1026397-34-1 [(S)-1-((S)-1-{(E)-(S)-4-(5-Methoxy-2,3-dihydro-indol-1-yl)-4-oxo-1-[2-(trityl-carbamoyl)-ethyl]-but-2-enylcarbamoyl}-2-phenyl-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid benzyl ester 
• 1026690-46-9 [(S)-1-((S)-1-{(E)-(S)-4-(7-Chloro-2,3-dihydro-indol-1-yl)-4-oxo-1-[2-(trityl-carbamoyl)-ethyl]-but-2-enylcarbamoyl}-2-phenyl-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid benzyl ester 

Relevant academic research and scientific papers

Glutamine vinyl ester proteasome inhibitors selective for trypsin-like (β2) subunit

Here we report the study of a new series of peptide-based proteasome inhibitors with a vinyl ester moiety at C-terminal. The presence of Tic, a rigid analogue of phenylalanine, in the central portion of some derivatives is not favourable for the activity.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure- activity studies

The structure-based design, chemical synthesis, and biological evaluation of various peptidederived human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds are comprised of an ethyl propenoate Michael acceptor moiety and a tripeptidyl binding determinant. The systematic modification of each amino acid residue present in the binding determinant as well as the N-terminal functionality is described. Such modifications are shown to provide irreversible HRV-14 3CP inhibitors with anti-3CP activities (k(obs)/[I]) ranging from 60 to 280 000 M-1 s-1 and antiviral EC50's which approach 0.15 μM. An optimized inhibitor which incorporates several improvements identified by the structure-activity studies is also described. This molecule displays very rapid irreversible inhibition of HRV-14 3CP (k(obs)/[I] = 800 000 M-1 s-1) and potent antiviral activity against HRV-14 in cell culture (EC50 = 0.056 μM). A 1.9 A? crystal structure of an S-alkylthiocarbamate-containing inhibitor complexed with HRV-2 3CP is also detailed.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structre-activity studies

The structure-based design, chemical synthesis, and biological evaluation of peptide-derived human rhinovirus (HRV) 3C protease (3CP) inhibitors are described. These compounds incorporate various Michael acceptor moieties and are shown to irreversibly bin